Cargando…

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

Detalles Bibliográficos
Autores principales:	Shah, Vallari, Sherborne, Amy L., Johnson, David C., Ellis, Sidra, Price, Amy, Chowdhury, Farzana, Kendall, Jack, Jenner, Matthew W., Drayson, Mark T., Owen, Roger G., Gregory, Walter M., Morgan, Gareth J., Davies, Faith E., Cook, Gordon, Cairns, David A., Houlston, Richard S., Jackson, Graham, Kaiser, Martin F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584474/ https://www.ncbi.nlm.nih.gov/pubmed/32157174 http://dx.doi.org/10.1038/s41375-020-0750-z

Ejemplares similares

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
por: Croft, James, et al.
Publicado: (2020)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
por: Coulson, Amy Beth, et al.
Publicado: (2022)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
por: Jones, John R., et al.
Publicado: (2019)

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
por: Shah, V, et al.
Publicado: (2018)

An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
por: Hoang, Phuc H., et al.
Publicado: (2020)

Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report
por: Shah, Vallari, et al.
Publicado: (2017)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
por: Chacon, Aurelia, et al.
Publicado: (2023)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Induction Treatment in Transplant-eligible Multiple Myeloma
por: Quinn, J., et al.
Publicado: (2021)

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma
por: Mitchell, Jonathan S., et al.
Publicado: (2015)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
por: Bennink, M. Christine, et al.
Publicado: (2022)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Regions of homozygosity as risk factors for multiple myeloma
por: Went, Molly, et al.
Publicado: (2019)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2011)

Mutational processes contributing to the development of multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2019)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Impact of mitochondrial DNA mutations in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2020)

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma
por: Morris, Treen Carson Michael, et al.
Publicado: (2021)

What are genome-wide association studies telling us about B-cell tumor development?
por: Sherborne, Amy L, et al.
Publicado: (2010)

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
por: Kropff, Martin, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_bhgirb4bqql66eok060le55lr5